GLP-1, GIP, and glucagon name different receptor axes, not one weight-loss drug class. In the Longeva/Incretin/Tripept catalog each axis maps to a distinct RUO molecule.
Three axes
- GLP-1 mono: semaglutide, liraglutide (Incretin)
- GLP-1 + GIP: tirzepatide (Incretin); see Mounjaro editorial
- Triple (+ glucagon): retatrutide on Tripept only
Educational primer only. Research use only framing applies to all RUO samples cited here [1][2][3][4][5].